See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The dosage of Cosentyx can vary depending on the severity of the disease being treated.

For plaque psoriasis, the recommended dosage for adults is 300 mg (as two 150 mg injections) at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks [1]. However, for patients with moderate to severe plaque psoriasis, the dosage may be increased to 300 mg every 2 weeks [1].

For psoriatic arthritis, the recommended dosage for adults is 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [1]. For ankylosing spondylitis, the recommended dosage for adults is 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks [1].

It is important to note that the dosage may be adjusted based on the patient's response to treatment and the severity of their disease [1]. Additionally, patients with renal or hepatic impairment may require dose adjustments [1].

In summary, the severity of the disease being treated can affect the dosing of Cosentyx. The medication is typically administered at a higher dosage for patients with moderate to severe plaque psoriasis, and the frequency of administration may be increased for patients who do not respond to the initial dosing regimen.

Sources:
[1] <https://www.drugs.com/cosentyx.html>
[2] <https://www.drugpatentwatch.com/drugs/cosentyx>